CLBS News and Press, Caladrius Biosciences Inc.

Caladrius Biosciences ( NASDAQ: CLBS ) announced that its stockholders approved all of the merger-related proposals by Caladrius and Cend Therapeutics, and the transactions contemplated thereby, including the Merger and the issuance of shares of Caladrius’ common stock ...

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of ...

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced tha...

Cend Therapeutics is collaborating with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) to evaluate CEND-1 in combination with Roche's Tecentriq (atezolizumab), and standard-of-care chemotherapy, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Under the agr...

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial investment in Cend BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 202...

Caladrius Biosciences, Inc. (CLBS) Q2 2022 Results Conference Call August 04, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO Kristen Buck - EVP, Research and Development & CMO James ...

Caladrius Biosciences press release ( NASDAQ: CLBS ): Q2 GAAP EPS of -$0.11 beats by $0.01 . As of June 30, 2022, the company had cash, cash equivalents and marketable securities of approximately $73 million. Merger with Cend Therapeutics remains on track to c...

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIR...

BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, announced today the ...